Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015',

In this issue

Home Eurosurveillance Edition  2016: Volume 21/ Issue 7 Article 5
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 21, Issue 7, 18 February 2016
Kempf, Heudorf, and on behalf of the authors of the original articles: Author’s reply: Is there a need for special treatment of refugees at hospital admission?

+ Author affiliations

Citation style for this article: Kempf VA, Heudorf U, on behalf of the authors of the original articles. Author’s reply: Is there a need for special treatment of refugees at hospital admission?. Euro Surveill. 2016;21(7):pii=30138. DOI:

Received:16 February 2016; Accepted:18 February 2016

To the editor: We would like to thank Walter and colleagues for their comment [1] on our respective investigations published in Eurosurveillance [2,3]. While we agree with many of the statements made, we would nevertheless like to clarify the following points:

The Robert Koch Institute published recommendations for multidrug-resistant organisms (MDRO) screening of refugees on hospital admission already in October 2015 [4]. This document stated that according to the recommendations of the German Commission of Hospital Hygiene and Infection Prevention screening for multidrug-resistant organisms (MDRO) on hospital admission is necessary for patients coming from regions with high prevalence rates for MDRO, with previous contact to the health system in their country of origin or on route. Furthermore it points out that screening should encompass meticillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant bacteria, only [5].

Infection control measures always represent a trade-off between patient safety and best medical treatment. We have shown that (i) the prevalence of MRSA is significantly higher in refugees (REF) (5.6%) than in a comparison group of resident population not admitted from a refugee accommodation (NREF) (1.2%) which itself justifies pre-emptive isolation, (ii) the prevalence of extended spectrum beta-lactamase (ESBL)-producing bacteria is significantly higher in REF which indeed has no infection control relevance, (iii) the prevalence of MDRGN with additional resistance to fluoroquinolones (so called 3MRGN in Germany) is significantly higher in REF which implies clearly consequences for hospital hygiene measures at least in special settings, e-g., intensive care units and (iv) the prevalence of carbapenem-resistant MDRGN strains (so called 4MRGN in Germany) in REF also, even if only slightly higher.

MDRO prevalence varies between distinct groups of patients and appropriate risk assessment has been established at Frankfurt University Hospital since five years e.g. for patients returning from high prevalence countries who have had contact with foreign healthcare systems. Increased MRSA, and, possibly also increased 3MRGN rates justify screening procedures and isolation in certain risk groups. Identification of risk groups and introduction of adequate infection control measures are genuine duties of hospital infection control and are uncomfortable, may affect medical treatment and are certainly costly. However, we feel that our approach is necessary to ensure best medical practice and safety for all of our patients regardless of their country of origin and without stigmatisation.

Conflict of interest

None declared.

Authors’ contributions

UH: literature work, writing. VK: literature work, writing.


  1. Walter J, Haller S, Hermes J, Arvand M, Abu Sin M, Eckmanns T. Letter to the editor: Is there a need for special treatment of refugees at hospital admission? Euro Surveill. 2016;21(7):pii=30137. DOI:

  2. Reinheimer C, Kempf VA, Göttig S, Hogardt M, Wichelhaus TA, O’Rourke F,  et al.  Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June‒December 2015. Euro Surveill. 2016;21(2):30110. DOI: 10.2807/1560-7917.ES.2016.21.2.30110 PMID: 26794850

  3. Heudorf U, Krackhardt B, Karathana M, Kleinkauf N, Zinn C. Multidrug-resistant bacteria in unaccompanied refugee minors arriving in Frankfurt am Main, Germany, October to November 2015. Euro Surveill. 2016;21(2):pii=30109. DOI:

  4. Robert Koch Institute (RKI). Screening von Asylsuchenden auf Multiresistente Erreger (MRE) Stellungnahme des Robert Koch-Instituts. [Screening of asylum seekers for multidrug resistant bacteria: statement of the Robert Koch-Insitute.] Berlin: RKI; 9 October 2015. German. Accessed from: on 5 December, 2015. No longer available, replaced online by [5].

  5. Robert Koch Institute (RKI). Stellungnahme des Robert Koch-Instituts zu Frage des Screenings von Asylsuchenden auf Multiresistente Erreger (MRE). [Statement of the Robert Koch Institute regarding screening of asylum seekers for multidrug resistant bacteria.] Berlin: RKI; 28 January 2016. German. Available from:

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.